Oral acetylsalicylic acid and prevalence of actinic keratosis
Autor(a) principal: | |
---|---|
Data de Publicação: | 2014 |
Outros Autores: | |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Institucional da UNESP |
Texto Completo: | http://dx.doi.org/10.1590/1806-9282.60.02.010 http://hdl.handle.net/11449/112205 |
Resumo: | Objective: To investigate the influence of a regular oral use of acetylsalicylic acid in the prevalence of actinic keratosis.Methods: A case-control study with dermatologic outpatients above 50 years of age assessed between 2009 and 2011. Cases were defined as those who had been under regular use of oral acetylsalicylic acid for more than six consecutive months. The assessment focused on: age, sex, skin-type, tobacco smoking, use of medication, occurrence of individual or family skin cancer, and sunscreen and sun exposure habits. Actinic keratoses were counted in the medial region of the face and upper limbs. Counts were adjusted by co-variables based on a generalized linear model.Results: A total of 74 cases and 216 controls were assessed. The median time of acetylsalicylic acid use was 36 months. Cases differed from controls as to the highest age, highest prevalence of use of angiotensin-converting enzyme inhibitors and fewer keratosis on the face and on the upper limbs (p < 0.05). The multivariate model showed that the use of acetylsalicylic acid was associated to lower counts of face actinic keratosis and upper-limb erythematous actinic keratosis (p < 0.05), regardless of other risk factors.Conclusion: The regular use of oral acetylsalicylic acid for more than six months was associated to a lower prevalence of actinic keratosis, especially facial and erythematous ones. |
id |
UNSP_25726fb347d9c9fd31a314ffd540cfcf |
---|---|
oai_identifier_str |
oai:repositorio.unesp.br:11449/112205 |
network_acronym_str |
UNSP |
network_name_str |
Repositório Institucional da UNESP |
repository_id_str |
2946 |
spelling |
Oral acetylsalicylic acid and prevalence of actinic keratosisactinic keratosisacetylsalicylic acidprevalencerisk factorsObjective: To investigate the influence of a regular oral use of acetylsalicylic acid in the prevalence of actinic keratosis.Methods: A case-control study with dermatologic outpatients above 50 years of age assessed between 2009 and 2011. Cases were defined as those who had been under regular use of oral acetylsalicylic acid for more than six consecutive months. The assessment focused on: age, sex, skin-type, tobacco smoking, use of medication, occurrence of individual or family skin cancer, and sunscreen and sun exposure habits. Actinic keratoses were counted in the medial region of the face and upper limbs. Counts were adjusted by co-variables based on a generalized linear model.Results: A total of 74 cases and 216 controls were assessed. The median time of acetylsalicylic acid use was 36 months. Cases differed from controls as to the highest age, highest prevalence of use of angiotensin-converting enzyme inhibitors and fewer keratosis on the face and on the upper limbs (p < 0.05). The multivariate model showed that the use of acetylsalicylic acid was associated to lower counts of face actinic keratosis and upper-limb erythematous actinic keratosis (p < 0.05), regardless of other risk factors.Conclusion: The regular use of oral acetylsalicylic acid for more than six months was associated to a lower prevalence of actinic keratosis, especially facial and erythematous ones.Sao Paulo State Univ, Botucatu Med Sch, UNESP, Dept Dermatol, BR-1861870 Botucatu, SP, BrazilSao Paulo State Univ, Botucatu Med Sch, UNESP, Dept Dermatol, BR-1861870 Botucatu, SP, BrazilAssociação Médica BrasileiraUniversidade Estadual Paulista (Unesp)Schmit, Juliano [UNESP]Miot, Hélio Amante [UNESP]2014-12-03T13:10:31Z2014-12-03T13:10:31Z2014-03-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article131-138application/pdfhttp://dx.doi.org/10.1590/1806-9282.60.02.010Revista Da Associacao Medica Brasileira. Sao Paulo: Assoc Medica Brasileira, v. 60, n. 2, p. 131-138, 2014.0104-4230http://hdl.handle.net/11449/11220510.1590/1806-9282.60.02.010S0104-42302014000200131WOS:000336012800008S0104-42302014000200131.pdf2543633050941005Web of Sciencereponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengRevista da Associação Médica Brasileira0.7360,265info:eu-repo/semantics/openAccess2024-08-14T18:46:19Zoai:repositorio.unesp.br:11449/112205Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T18:46:19Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false |
dc.title.none.fl_str_mv |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
title |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
spellingShingle |
Oral acetylsalicylic acid and prevalence of actinic keratosis Schmit, Juliano [UNESP] actinic keratosis acetylsalicylic acid prevalence risk factors |
title_short |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
title_full |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
title_fullStr |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
title_full_unstemmed |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
title_sort |
Oral acetylsalicylic acid and prevalence of actinic keratosis |
author |
Schmit, Juliano [UNESP] |
author_facet |
Schmit, Juliano [UNESP] Miot, Hélio Amante [UNESP] |
author_role |
author |
author2 |
Miot, Hélio Amante [UNESP] |
author2_role |
author |
dc.contributor.none.fl_str_mv |
Universidade Estadual Paulista (Unesp) |
dc.contributor.author.fl_str_mv |
Schmit, Juliano [UNESP] Miot, Hélio Amante [UNESP] |
dc.subject.por.fl_str_mv |
actinic keratosis acetylsalicylic acid prevalence risk factors |
topic |
actinic keratosis acetylsalicylic acid prevalence risk factors |
description |
Objective: To investigate the influence of a regular oral use of acetylsalicylic acid in the prevalence of actinic keratosis.Methods: A case-control study with dermatologic outpatients above 50 years of age assessed between 2009 and 2011. Cases were defined as those who had been under regular use of oral acetylsalicylic acid for more than six consecutive months. The assessment focused on: age, sex, skin-type, tobacco smoking, use of medication, occurrence of individual or family skin cancer, and sunscreen and sun exposure habits. Actinic keratoses were counted in the medial region of the face and upper limbs. Counts were adjusted by co-variables based on a generalized linear model.Results: A total of 74 cases and 216 controls were assessed. The median time of acetylsalicylic acid use was 36 months. Cases differed from controls as to the highest age, highest prevalence of use of angiotensin-converting enzyme inhibitors and fewer keratosis on the face and on the upper limbs (p < 0.05). The multivariate model showed that the use of acetylsalicylic acid was associated to lower counts of face actinic keratosis and upper-limb erythematous actinic keratosis (p < 0.05), regardless of other risk factors.Conclusion: The regular use of oral acetylsalicylic acid for more than six months was associated to a lower prevalence of actinic keratosis, especially facial and erythematous ones. |
publishDate |
2014 |
dc.date.none.fl_str_mv |
2014-12-03T13:10:31Z 2014-12-03T13:10:31Z 2014-03-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://dx.doi.org/10.1590/1806-9282.60.02.010 Revista Da Associacao Medica Brasileira. Sao Paulo: Assoc Medica Brasileira, v. 60, n. 2, p. 131-138, 2014. 0104-4230 http://hdl.handle.net/11449/112205 10.1590/1806-9282.60.02.010 S0104-42302014000200131 WOS:000336012800008 S0104-42302014000200131.pdf 2543633050941005 |
url |
http://dx.doi.org/10.1590/1806-9282.60.02.010 http://hdl.handle.net/11449/112205 |
identifier_str_mv |
Revista Da Associacao Medica Brasileira. Sao Paulo: Assoc Medica Brasileira, v. 60, n. 2, p. 131-138, 2014. 0104-4230 10.1590/1806-9282.60.02.010 S0104-42302014000200131 WOS:000336012800008 S0104-42302014000200131.pdf 2543633050941005 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
Revista da Associação Médica Brasileira 0.736 0,265 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
131-138 application/pdf |
dc.publisher.none.fl_str_mv |
Associação Médica Brasileira |
publisher.none.fl_str_mv |
Associação Médica Brasileira |
dc.source.none.fl_str_mv |
Web of Science reponame:Repositório Institucional da UNESP instname:Universidade Estadual Paulista (UNESP) instacron:UNESP |
instname_str |
Universidade Estadual Paulista (UNESP) |
instacron_str |
UNESP |
institution |
UNESP |
reponame_str |
Repositório Institucional da UNESP |
collection |
Repositório Institucional da UNESP |
repository.name.fl_str_mv |
Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP) |
repository.mail.fl_str_mv |
|
_version_ |
1808128196141383680 |